MedPath
NMPA Approval

Diazoxide Oral Suspension

国药准字H20243049

January 9, 2024

Drug Information

二氮嗪口服混悬液

口服混悬剂

30ml:1.5g

化学药品

January 9, 2024

Company Information

Applicant Company

安徽省宿州经济开发区金江路北侧

Manufacturing Company

安徽省宿州经济开发区金江路北侧

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

二氮嗪口服混悬液 - NMPA 批准文号 | MedPath